# Preoperative Amivantamab or Amivantamab and Carboplatin/Pemetrexed Treatment in Patients With Resectable Non-small-cell Lung Cancer Harboring Oncogenic EGFR Mutations (NEOpredict-EGFR)

> **NCT06784791** · PHASE2 · RECRUITING · sponsor: **University Hospital, Essen** · enrollment: 20 (estimated)

## Conditions studied

- Lung Cancer (NSCLC)

## Interventions

- **DRUG:** Amivantamab Intravenous
- **DRUG:** Carboplatin/Pemetrexed

## Key facts

- **NCT ID:** NCT06784791
- **Lead sponsor:** University Hospital, Essen
- **Sponsor class:** OTHER
- **Phase:** PHASE2
- **Study type:** INTERVENTIONAL
- **Status:** RECRUITING
- **Start date:** 2024-11-06
- **Primary completion:** 2027-07-31
- **Final completion:** 2027-12-31
- **Target enrollment:** 20 (ESTIMATED)
- **Last updated:** 2025-08-29


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT06784791

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT06784791, "Preoperative Amivantamab or Amivantamab and Carboplatin/Pemetrexed Treatment in Patients With Resectable Non-small-cell Lung Cancer Harboring Oncogenic EGFR Mutations (NEOpredict-EGFR)". Retrieved via AI Analytics 2026-06-02 from https://api.ai-analytics.org/clinical/NCT06784791. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*